The Journal of Precision Molecular and Clinical Oncology (JPMCO) is an international peer-reviewed scholarly journal dedicated to the publication of high-quality research in precision oncology, molecular medicine, translational cancer research, and clinical oncology. The journal provides a platform for the dissemination of innovative scientific discoveries that enhance the understanding of cancer biology and support the development of personalized approaches to cancer prevention, diagnosis, and treatment.
As advances in genomics, molecular diagnostics, immunotherapy, artificial intelligence, and targeted therapeutics continue to transform oncology, there is an increasing need for interdisciplinary collaboration and effective translation of scientific discoveries into clinical practice. JPMCO seeks to bridge the gap between laboratory research and patient care by publishing scientifically rigorous and clinically relevant studies that contribute to improving outcomes for individuals affected by cancer.
The journal welcomes contributions from researchers, clinicians, physician-scientists, molecular biologists, pathologists, geneticists, bioinformaticians, pharmacologists, and healthcare professionals worldwide. Through the publication of impactful research and scholarly communication, JPMCO aims to advance knowledge, encourage innovation, and support the continued evolution of precision medicine in oncology.
JPMCO is committed to maintaining the highest standards of scientific integrity, editorial excellence, and ethical publishing. Through a rigorous peer-review process and transparent editorial practices, the journal strives to provide a trusted forum for the exchange of knowledge that advances cancer research and clinical care.
We invite the global scientific community to explore, contribute to, and engage with JPMCO as we work together to advance the future of precision molecular and clinical oncology.
